358 related articles for article (PubMed ID: 32893093)
1. The Role of Immune Cells in Breast Tissue and Immunotherapy for the Treatment of Breast Cancer.
Goff SL; Danforth DN
Clin Breast Cancer; 2021 Feb; 21(1):e63-e73. PubMed ID: 32893093
[TBL] [Abstract][Full Text] [Related]
2. Immune cell quantitation in normal breast tissue lobules with and without lobulitis.
Degnim AC; Brahmbhatt RD; Radisky DC; Hoskin TL; Stallings-Mann M; Laudenschlager M; Mansfield A; Frost MH; Murphy L; Knutson K; Visscher DW
Breast Cancer Res Treat; 2014 Apr; 144(3):539-49. PubMed ID: 24596048
[TBL] [Abstract][Full Text] [Related]
3. Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication.
Burugu S; Asleh-Aburaya K; Nielsen TO
Breast Cancer; 2017 Jan; 24(1):3-15. PubMed ID: 27138387
[TBL] [Abstract][Full Text] [Related]
4. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer.
García-Martínez E; Gil GL; Benito AC; González-Billalabeitia E; Conesa MA; García García T; García-Garre E; Vicente V; Ayala de la Peña F
Breast Cancer Res; 2014 Nov; 16(6):488. PubMed ID: 25432519
[TBL] [Abstract][Full Text] [Related]
5. Ductal carcinoma in situ of the breast: immune cell composition according to subtype.
Agahozo MC; van Bockstal MR; Groenendijk FH; van den Bosch TPP; Westenend PJ; van Deurzen CHM
Mod Pathol; 2020 Feb; 33(2):196-205. PubMed ID: 31375764
[TBL] [Abstract][Full Text] [Related]
6. Differential regulation and function of tumor-infiltrating T cells in different stages of breast cancer patients.
Zhu S; Lin J; Qiao G; Xu Y; Zou H
Tumour Biol; 2015 Sep; 36(10):7907-13. PubMed ID: 25953262
[TBL] [Abstract][Full Text] [Related]
7. Prognostic role of immune infiltrates in breast ductal carcinoma in situ.
Chen XY; Yeong J; Thike AA; Bay BH; Tan PH
Breast Cancer Res Treat; 2019 Aug; 177(1):17-27. PubMed ID: 31134489
[TBL] [Abstract][Full Text] [Related]
8. Immune response and stromal changes in ductal carcinoma in situ of the breast are subtype dependent.
Agahozo MC; Westenend PJ; van Bockstal MR; Hansum T; Giang J; Matlung SE; van Deurzen CHM
Mod Pathol; 2020 Sep; 33(9):1773-1782. PubMed ID: 32341499
[TBL] [Abstract][Full Text] [Related]
9. CD4+ and CD8+ T cells have opposing roles in breast cancer progression and outcome.
Huang Y; Ma C; Zhang Q; Ye J; Wang F; Zhang Y; Hunborg P; Varvares MA; Hoft DF; Hsueh EC; Peng G
Oncotarget; 2015 Jul; 6(19):17462-78. PubMed ID: 25968569
[TBL] [Abstract][Full Text] [Related]
10. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY
Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826
[TBL] [Abstract][Full Text] [Related]
11. Alterations in the Immune Cell Composition in Premalignant Breast Tissue that Precede Breast Cancer Development.
Degnim AC; Hoskin TL; Arshad M; Frost MH; Winham SJ; Brahmbhatt RA; Pena A; Carter JM; Stallings-Mann ML; Murphy LM; Miller EE; Denison LA; Vachon CM; Knutson KL; Radisky DC; Visscher DW
Clin Cancer Res; 2017 Jul; 23(14):3945-3952. PubMed ID: 28126725
[No Abstract] [Full Text] [Related]
12. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic significance of intratumoral CD8+ tumor-infiltrating lymphocytes in medullary carcinoma.
Igari F; Sato E; Horimoto Y; Takahashi Y; Isomura T; Arakawa A; Kitano S; Saito M
Hum Pathol; 2017 Dec; 70():129-138. PubMed ID: 29122657
[TBL] [Abstract][Full Text] [Related]
14. Expression of PD-1 on CD4
Zhao YJ; Zhang J; Shi F; Hu ZP; Wu JP; Wu GJ; Wang RB; Zhou Q; Chang H; Li YN; Song QK
J Immunol Res; 2018; 2018():5690258. PubMed ID: 30069490
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer.
Nelson MA; Ngamcherdtrakul W; Luoh SW; Yantasee W
Cancer Metastasis Rev; 2021 Jun; 40(2):519-536. PubMed ID: 33963482
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast.
Thompson ED; Taube JM; Asch-Kendrick RJ; Ogurtsova A; Xu H; Sharma R; Meeker A; Argani P; Emens LA; Cimino-Mathews A
Mod Pathol; 2017 Nov; 30(11):1551-1560. PubMed ID: 28731046
[TBL] [Abstract][Full Text] [Related]
17. Role of CXCL10 in the progression of in situ to invasive carcinoma of the breast.
Kim M; Choi HY; Woo JW; Chung YR; Park SY
Sci Rep; 2021 Sep; 11(1):18007. PubMed ID: 34504204
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the mononuclear inflammatory cell infiltrate in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas: preliminary observations.
Hussein MR; Hassan HI
J Clin Pathol; 2006 Sep; 59(9):972-7. PubMed ID: 16935972
[TBL] [Abstract][Full Text] [Related]
19. The immune microenvironment of breast ductal carcinoma in situ.
Thompson E; Taube JM; Elwood H; Sharma R; Meeker A; Warzecha HN; Argani P; Cimino-Mathews A; Emens LA
Mod Pathol; 2016 Mar; 29(3):249-58. PubMed ID: 26769139
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of S1PR1 and its correlation with immune infiltrates in breast and lung cancers.
Zhong L; Xie L; Yang Z; Li L; Song S; Cao D; Liu Y
BMC Cancer; 2020 Aug; 20(1):766. PubMed ID: 32799825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
